CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
| Revenues | ||||
| Total revenues | $ 47,086 | $ 25,438 | $ 148,466 | $ 55,728 |
| Cost of sales | ||||
| Total cost of sales | 47,395 | 21,483 | 141,706 | 49,988 |
| Gross profit | (309) | 3,955 | 6,760 | 5,740 |
| Operating expenses | ||||
| Research and development | 22,382 | 19,311 | 78,357 | 45,820 |
| Sales and marketing | 16,204 | 13,224 | 56,299 | 29,567 |
| General and administrative | 18,924 | 19,833 | 62,472 | 46,821 |
| In-process research and development assets acquired | 15,181 | 25,581 | ||
| Goodwill impairment | 229,500 | |||
| Total operating expenses | 57,510 | 67,549 | 426,628 | 147,789 |
| Loss from operations | (57,819) | (63,594) | (419,868) | (142,049) |
| Change in fair value of warrant liability | (56,576) | |||
| Interest expense | (680) | (12) | (1,281) | (137) |
| Interest and other (expense) income, net | (1,677) | (3,796) | (8,443) | (3,166) |
| Loss before income taxes | (60,176) | (67,402) | (429,592) | (201,928) |
| Income tax (expense) benefit | (598) | 523 | 1,602 | 32,761 |
| Net loss | $ (60,774) | $ (66,879) | $ (427,990) | $ (169,167) |
| Net loss per share-Basic | $ (0.19) | $ (0.26) | $ (1.36) | $ (0.67) |
| Net loss per share-Diluted | $ (0.19) | $ (0.26) | $ (1.36) | $ (0.67) |
| Weighted average shares outstanding, basic | 316,007,716 | 260,555,655 | 313,901,704 | 251,467,644 |
| Weighted average shares outstanding, diluted | 316,007,716 | 260,555,655 | 313,901,704 | 251,467,644 |
| Products | ||||
| Revenues | ||||
| Total revenues | $ 42,937 | $ 23,949 | $ 135,085 | $ 51,820 |
| Cost of sales | ||||
| Total cost of sales | 43,639 | 20,450 | 130,454 | 46,427 |
| Services | ||||
| Revenues | ||||
| Total revenues | 4,149 | 1,489 | 13,381 | 3,908 |
| Cost of sales | ||||
| Total cost of sales | $ 3,756 | $ 1,033 | $ 11,252 | $ 3,561 |
| X | ||||||||||
- Definition The amount of interest income and other income (expense), net recognized during period. No definition available.
|
| X | ||||||||||
- Definition The amount of acquired research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. No definition available.
|
| X | ||||||||||
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The net amount of operating interest income (expense). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|